Modern treatment strategies in polycythemia vera

Seminars in Hematology

Volumn 40, Issue 1 SUPPL. 1, 2003, Pages 26-29

  Gilbert, Harriet S ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA;

AGE; ANEMIA; BLEEDING; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; ERYTHROID CELL; ERYTHROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMOGENESIS; MEGAKARYOCYTE; MENTAL DISEASE; METASTASIS; MUTAGENICITY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTE; THROMBOCYTE COUNT;

EID: 0037251058     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(03)70056-0     Document Type: Conference Paper

References (40)

1. Berk PD, Goldberg JD, Donovan PB, et al: Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132-143, 1986
2. Berk PD, Wasserman JD, Fruchtman SM, et al: Treatment of polycythemia vera: A summary of clinical trials conducted by the Polycythemia Vera Study Group, in Wasserman LR, Berk PD, Berlin NI (eds): Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA, Saunders, 1995, pp 102-113
3. Kannel WB, Gordon T, Wolf PA, et al: Hemoglobin and the risk of cerebral infarction: The Framingham Study. Stroke 3:409-420, 1972
4. Tohgi H, Yamanouchi H, Murakami M, et al: Importance of the hematocrit as a risk factor in cerebral infarction. Stroke 9:369-374, 1978
5. Di Pollina L, Mulligan R, Juillerat VdL, et al: Cognitive impairment in polycythemia vera: Partial reversibility upon lowering of the hematocrit. Eur Neurol 44:57-59, 2000
6. Thomas DJ, du Boulay GH, Marshall J, et al: Cerebral bloodflow in polycythaemia. Lancet 2:161-163, 1977
7. Willison JR, Thomas DJ, du Boulay GH, et al: Effect of high haematocrit on alertness. Lancet 1:846-848, 1980
8. Wade JP: Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection. Brain 106:513-523, 1983
9. Messinezy M, Nunan TO, Pearson TC: Brain perfusion in polycythaemia using 99TcmHMPAO: Effect of treatment. Eur J Haematol 51:120-121, 1993
10. EORTC: Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (EORTC). Br J Cancer 44:75-80, 1981
11. Berk PD, Goldberg JD, Silverstein MN, et al: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441-447, 1981
12. Brusamolino E, Salvaneschi L, Canevari A, et al: Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J Clin Oncol 2:558-561, 1984
13. Murphy S: Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 78:622-626, 1997
14. Tatarsky I, Sharon R: Management of polycythemia vera with hydroxyurea. Semin Hematol 34:24-28, 1997
15. Gilbert HS: Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol 36:19-22, 1999
16. Gilbert HS: Polycythemia vera, in Rakel RE (ed): Conn's 2000: Latest Approved Methods of Treatment for the Practicing Physician. Philadelphia, PA, Saunders, 2000, pp 445-447
17. Kaplan ME, Mack K, Goldberg JD, et al: Long-term management of polycythemia vera with hydroxyurea: A progress report. Semin Hematol 23:167-171, 1986
18. Weinfeld A, Swolin B, Westin J: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52:134-139, 1994
19. Fruchtman SM, Mack K, Kaplan ME, et al: From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17-23, 1997
20. Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91:616-622, 1998
21. Tothova E, Fricova M, Stecova N, et al: Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. Neoplasma 48:389-392, 2001
22. Mavrogianni D, Viniou N, Michali E, et al: Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. Int J Hematol 75:394-400, 2002
23. Finazzi G, Ruggeri M, Rodeghiero F, et al: Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 110:577-583, 2000
24. Tefferi A, Elliott MA, Kao PC, et al: Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood 96:1582-1584, 2000
25. Steensma DP, Harrison CN, Tefferi A: Hydroxyurea-associated platelet count oscillations in polycythemia vera: A report of four new cases and a review. Leuk Lymphoma 42:1243-1253, 2001
26. Ravandi-Kashani F, Cortes J, Cohen P, et al: Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35:109-118, 1999
27. Silver RT: A new treatment for polycythemia vera: Recombinant interferon alfa. Blood 76:664-665, 1990
28. Silver RT: Interferon alfa: Effects of long-term treatment for polycythemia vera. Semin Hematol 34:40-50, 1997
29. Tefferi A, Elliott MA, Solberg LA Jr, et al: New drugs in essential thrombocythemia and polycythemia vera. Blood Rev 11:1-7, 1997
30. Elliott MA, Tefferi A: Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 23:463-472, 1997
31. Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy. Cancer 83: 1205-1213, 1998
32. Merup M, Aberg W, Lofvenberg E, et al: Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 41:50-55, 2002
33. Silverstein MN, Petitt RM, Solberg LA Jr, et al: Anagrelide: A new drug for treating thrombocytosis. N Engl J Med 318: 1292-1294, 1988
34. Petitt RM, Silverstein MN, Petrone ME: Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51-54, 1997
35. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 92:69-76, 1992
36. Landaw SA: Acute leukemia in polycythemia vera, in Wasserman LR, Berk PD, Berlin NI (eds): Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA, Saunders, 1995, pp 154-165
37. Storen EC, Tefferi A: Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863-866, 2001
38. Regev A, Stark P, Blickstein D, et al: Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 56:168-172, 1997
39. Lengfelder E, Hochhaus A, Kronawitter U, et al: Should a platelet limit of 600 × 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 100:15-23, 1998
40. Gilbert HS: Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 29:22-27, 2002